Physician profile
Daniel Barfield
NPI 1578581831
$3,140.52
in general payments reported to CMS, 2019-2025
27 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $243 · 2021: $1,513 · 2022: $177 · 2023: $260 · 2024: $232 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,076.29 | 2021 | |
| Astellas Pharma US INC | $530.21 | 2019-2025 | Veozah |
| Abbvie INC. | $294.06 | 2019-2022 | |
| Organon LLC | $185.67 | 2022-2025 | Nexplanon, Jada System |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Optumhealth Care Solutions, LLC | $103.49 | 2023-2025 | Vivify Health Care Team Portal, Zyno Solutions, Vivify Health Care Team Portal 001 |
| Daiichi Sankyo INC. | $100.22 | 2023-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $95.75 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $90.21 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $51.96 | 2019-2021 | |
| Hologic Sales and Service, LLC | $50.86 | 2021 | |
| Pfizer INC. | $47.01 | 2025 | |
| Merck Sharp & Dohme LLC | $45.34 | 2019-2021 | |
| Medtronic, INC. | $39.09 | 2022-2024 | Venaseal |
| Siemens Medical Solutions USA, INC. | $36.96 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $35.34 | 2025 | Myfembree |
| Olympus America INC. | $30.30 | 2019-2023 | 4k Camera Head |
| Biogen, INC. | $29.28 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $23.37 | 2023 | Mara Console |
| Roche Diagnostics Corporation | $23.32 | 2019 | |
| Evofem Biosciences, INC. | $23.27 | 2021 | |
| Boston Scientific Corporation | $22.34 | 2022 | |
| Covidien LP | $21.52 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.62 | 2023 | Adthyza |
| Acella Pharmaceuticals, LLC | $15.16 | 2024 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Barfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.